We combine deep iPSC knowledge with over a decade of experience in developing differentiation procedures for more than 10 cell types. Everyday we are one step closer to the cell type you need.
Derived from Cynomolgus iPSCs, we are developing the first-ever NHP ventricular cardiomyocytes for toxicity and safety pharmacology research.
Want to be among the first to experience this groundbreaking product once launched?
Register for Early Access
Discover where we are at with your desire product and the unique benefits of early request
The Ncardia team generates a project plan that aligns with your timelines and milestones
Through transparent communication with your team, we work to deliver in the shortest possible timeframe.
We provide constant supply adjust to your time and scale requirements.
Learn more about our approach and experience with previous projects
As more and more researchers look to capitalize on the unique value of iPSCs, they look to Ncardia as the uniquely qualified collaborator to join them on their journeys. We’re ready to help make your next step the very best it can be.
